Efficacy of cabazitaxel (CABA) rechallenge in heavily-treated patients with metastatic castration-resistant prostate cancer (mCRPC).

Constance Thibault,Jean-Christophe Eymard,Anne Claire Hardy-Bessard,Alison J. Birtle,Michael Krainer,Giulia Baciarello,Aude Flechon,Sylvestre Le Moulec,Dominique Spaeth,Brigitte Laguerre,Orazio Caffo,Jean-Laurent Deville,Philippe Beuzeboc,Ali Hasbini,Marine Gross-Goupil,Carole Helissey,Mostefa Bennamoun,S. Oudard

Efficacy of cabazitaxel (CABA) rechallenge in heavily-treated patients with metastatic castration-resistant prostate cancer (mCRPC).

2017

Constance Thibault
Jean-Christophe Eymard
Anne Claire Hardy-Bessard
Alison J. Birtle
Michael Krainer
Giulia Baciarello
Aude Flechon
Sylvestre Le Moulec
Dominique Spaeth
Brigitte Laguerre
Orazio Caffo
Jean-Laurent Deville
Philippe Beuzeboc
Ali Hasbini
Marine Gross-Goupil
Carole Helissey
Mostefa Bennamoun
S. Oudard

5033Background: Only 2 chemotherapies have shown an overall survival (OS) benefit in mCRPC: docetaxel (DOC) and CABA. In patients (pts) previously treated with a new hormonal therapy (NHT: enzaluta...

Keywords:

Cabazitaxel
Prostate cancer
Castration
Pathology
Cancer research
Medicine
previously treated
Oncology
overall survival
Docetaxel
in patient
castration resistant
Hormonal therapy
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations